Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer von Miller, Richard A, Luke, Jason John, Hu, Shenshen, Mahabhashyam, Suresh, Jones, William B, Marron, Thomas, Merchan, Jaime R, Hughes, Brett G M, Willingham, Stephen B

Volltext

325 Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells and memory T... von Criner, Gerard, Mobasher, Mehrdad, Hill, Craig, Hu, Shenshen, Mahabhashyam, Suresh, Brody, Joshua, Marron, Thomas, Willingham, Stephen, Miller, Richard

Volltext

701 Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: clinical activity in human papilloma virus positive (HPV) head and neck squam... von Luke, Jason, Merchan, Jaime, Hughes, Brett, Sosman, Jeffrey, Tripathi, Abhishek, Puzanov, Igor, Marron, Thomas, Marrone, Kristen, Hill, Craig, Janc, James, Rudnick, Jenny, Hu, Shenshen, Mobasher, Mehrdad, Mahabhashyam, Suresh, Miller, Richard

Volltext

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas von Song, Yuqin, Ding, Ning, Yoon, Dok Hyun, Reneau, John C., Wilcox, Ryan A., Kim, Won Seog, Kim, Youn H., Khodadoust, Michael S., Feldman, Tatyana A., Yannakou, Costas K., Giri, Pratyush, Brammer, Jonathan E, Hsu, Lih-Yun, Yuan, Hongwei, Verner, Erik, Mahabhashyam, Suresh, Miller, Richard A.

Volltext

Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma von Khodadoust, Michael S., Feldman, Tatyana A., Yoon, Dok Hyun, Yannakou, Costas K., Radeski, Dejan, Kim, Youn H., Mehta-Shah, Neha, Khot, Amit, Wilcox, Ryan A., Kim, Won Seog, Horwitz, Steven M., Buggy, Joseph J., Hotson, Andrew, Hill, Craig M., Munneke, Brian, Mahabhashyam, Suresh, Miller, Richard A., Janc, James W., Mobasher, Mehrdad

Volltext

Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors von Sullivan, Ryan J., Hong, David S., Tolcher, Anthony W., Patnaik, Amita, Shapiro, Geoffrey, Chmielowski, Bartosz, Ribas, Antoni, Brail, Les H., Roberts, Jennifer, Lee, Lucy, O'Connell, Brenda, Kutok, Jeffrey Lorne, Mahabhashyam, Suresh, Dansky Ullmann, Claudio, Postow, Michael A., Wolchok, Jedd D.

Volltext